|The Viral Hepatitis Program acknowledges that community testing programs are in a unique position to identify people at risk for hepatitis C, to provide testing and linkage to care. The following information is provided to support efficient community testing for programs that use rapid hepatitis C tests.
There are 116,000 people estimated to be living with chronic hepatitis C in New York City; unfortunately, many are asymptomatic and unaware of their status. Hepatitis C is caused by a virus transmitted through blood that can lead to liver cancer and premature death. People born from 1945-1965, people who have injected drugs, people living with HIV, and men who have sex with men are at risk for hepatitis C and should be tested. Fortunately, hepatitis C can be treated and cured in 8-12 weeks with antiviral medications. However, a person can get infected with hepatitis C again after cure – if they are exposed to infected blood. Our goal is to remind programs that use rapid hepatitis C test kits of the recommended testing and reporting methods for hepatitis C.
Key factors to keep in mind:
There are two phases of hepatitis C infection:
Resources for Community Hepatitis C Testing
Contact Hep@health.nyc.gov or call our Hepatitis Navigation Warm-line (917) 890-0834 for assistance helping your patients get tested, treated and cured.
Diana Diaz Muñoz, Hep C Community Navigation Programs
Viral Hepatitis Program, NYC Health Department
CC: Nirah Johnson, Ann Winters
Advocacy, HepCX News, News, Hepatitis C, Medicaid, Open for Comment, Pharmaceutical
On February 26th, the New York State Drug Utilization Review Board will meet to review and recommend NYS Medicaid clinical criteria for Viekira Pak - the most recently approved Hepatitis C therapy - marketed by AbbVie.
HepCX News, News, Hepatitis C, Pharmaceutical
The FDA has approved the drug Epclusa to treat adult patients with chronic Hep C both with and without cirrhosis.
Article | Effect of Hepatocellular Carcinoma on Mortality Among Individuals With Hep B or Hep C Infection in NYC, 2001–2012Articles, HepCX News, Publications
We describe the mortality profile of NYC residents with HBV or HCV, emphasizing the contributions of HCC and HIV coinfection.
HepCX News, News
A successful Viral Hepatitis Research Symposium took place on May 24, 2018 at Rockefeller University. This event brought together more than 200 local medical providers, laboratory directors, community service providers, policy-makers and other stakeholders, and DOHMH staff to r...
HepCX News, Research, Call for Abstracts
Now is the time to submit your abstract to become part of the 2018 NYC Viral Hepatitis Research Symposium! The primary focus of the meeting is on addressing viral hepatitis in special populations. Authors are encouraged to submit abstracts on their research and health care evalua...
Advocacy, Awareness Day Committee, HepCX News, News
The new effort aims to stop the Hepatitis C virus in its tracks by increasing access to medications that can cure Hepatitis C and expanding programs to connect New Yorkers in high-risk communities with wrap-around Hepatitis C prevention, screenings and treatment services.
- Job | Hepline Specialist @ American Liver FOundation January 16, 2020
- REACH OUT – Support Loved One who is Using Opioids @ Mount Sinai REACH Program January 6, 2020
- Joint Hep B Coalition and Hep C Task Force Meeting Highlights | 12-11-2019 December 26, 2019
- Job | Hep B Navigator @ Philadelphia Health Dept. December 23, 2019
- AIDS Institute Drug User Health Capacity Building Initiative December 11, 2019
- Internship | Project AHEAD @ Charles B Wang Community Health Center December 10, 2019
- Job | Hepatitis Clinical Capacity Building Program Assistant Intern (for Master students ONLY) @ NYC Health Department December 6, 2019